Article

New VP oversees pegaptanib development

New York-Eyetech Pharmaceuticals has appointed Barrett Katz, MD, as its vice president of medical strategy.

New York-Eyetech Pharmaceuticals has appointed Barrett Katz, MD, as its vice president of medical strategy.

Dr. Katz, who was most recently chairman of the department of ophthalmology at George Washington University School of Medicine and a professor of ophthalmology, neurology, and neurosurgery there, will help guide the phase IIIb/IV clinical protocols and trials for pegaptanib sodium injection (Macugen).

The drug, which is under FDA review for the treatment of wet age-related macular degeneration, is being developed with Pfizer Ophthalmics. Dr. Katz will serve as senior liaison to the new Pfizer Inc. division.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.